Skip to main content

Table 1 Selection criteria for the VERTICAL study

From: Comparing conVEntional RadioTherapy with stereotactIC body radiotherapy in patients with spinAL metastases: study protocol for an randomized controlled trial following the cohort multiple randomized controlled trial design

Inclusion criteria Exclusion criteria
Participant in PRESENT cohort Lesion in C1, and C2
Filling out PRESENT-questionnaires Contraindication for MRI if MRI is indicated
Broad consent for randomization to experimental interventions Radiosensitive histology such as multiple myeloma
Histologic proof of malignancy Unable to undergo SBRT treatment
Imaging evidence of bone metastases Patient with < 3 months life expectancy
For spinal lesions, per lesion no more than 3 consecutive spine segments involved with one unaffected vertebral body above and below Chemotherapy or systemic radionuclide delivery within 24 h before and after SBRT
No more than 2 painful lesions needing treatment Previous EBRT or SBRT to same level
For spinal lesions, no compression of spinal cord For spinal lesions, unstable spine requiring surgical stabilization
No or mild neurological signsa Severe, worsening or progressive neurological deficit
KPS > 50 and pain score > 3b  
  1. VERTICAL randomized controlled trial comparing conVEntional RadioTherapy with stereotactIC body radiotherapy in patients with spinAL metastases; PRESENT Prospective Evaluation of interventional StudiEs on boNe meTastases (PRESENT) cohort; MRI magnetic resonance imaging; SBRT stereotactic body radiotherapy; EBRT external beam radiotherapy; KPS Karnofsky performance score
  2. aradiculopathy, dermatomal sensory change, and muscle strength of involved extremity is Medical Research Counsil (MRC) 4/5
  3. bon a scale from 0 to 10